Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms

Author(s): Vivek Verma, Nirmal Singh, Amteshwar Singh Jaggi

Journal Name: Current Neuropharmacology

Volume 12 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


Pregabalin is an antagonist of voltage gated Ca2+ channels and specifically binds to alpha-2-delta subunit to produce antiepileptic and analgesic actions. It successfully alleviates the symptoms of various types of neuropathic pain and presents itself as a first line therapeutic agent with remarkable safety and efficacy. Preclinical studies in various animal models of neuropathic pain have shown its effectiveness in treating the symptoms like allodynia and hyperalgesia. Clinical studies in different age groups and in different types of neuropathic pain (peripheral diabetic neuropathy, fibromyalgia, post-herpetic neuralgia, cancer chemotherapy-induced neuropathic pain) have projected it as the most effective agent either as monotherapy or in combined regimens in terms of cost effectiveness, tolerability and overall improvement in neuropathic pain states. Preclinical studies employing pregabalin in different neuropathic pain models have explored various molecular targets and the signaling systems including Ca2+ channel-mediated neurotransmitter release, activation of excitatory amino acid transporters (EAATs), potassium channels and inhibition of pathways involving inflammatory mediators. The present review summarizes the important aspects of pregabalin as analgesic in preclinical and clinical studies as well as focuses on the possible mechanisms.

Keywords: Pregabalin, neuropathic pain, diabetic neuropathy, post-herpetic neuralgia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 17 January, 2014
Page: [44 - 56]
Pages: 13
DOI: 10.2174/1570159X1201140117162802

Article Metrics

PDF: 86